Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7534459rdf:typepubmed:Citationlld:pubmed
pubmed-article:7534459lifeskim:mentionsumls-concept:C0013227lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C0031640lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C0282555lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C1151015lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C0205164lld:lifeskim
pubmed-article:7534459lifeskim:mentionsumls-concept:C0073071lld:lifeskim
pubmed-article:7534459pubmed:issue1lld:pubmed
pubmed-article:7534459pubmed:dateCreated1995-4-19lld:pubmed
pubmed-article:7534459pubmed:abstractTextMY-1250 (5,6-dihydro-7,8-dimethyl-4,5-dioxo-4H-pyrano [3,2-c]quinoline-2-carboxylic acid, CAS 63768-47-8), a major metabolite of the antiallergic drug repirinast (MY-5116, CAS 73080-51-0), inhibits antigen-induced histamine release from rat peritoneal mast cells. MY-1250 causes a rapid increase in cyclic adenosine monophosphate (AMP) levels in rat peritoneal mast cells. MY-1250 inhibited cyclic AMP phosphodiesterase activities from rat peritoneal cells and guinea pig lung tissue in a concentration dependent manner with IC50 values of 2000 mumol/l and 1670 mumol/l, respectively. However, MY-1250 showed no effect on adenylate cyclase activity from rat peritoneal cells. These results suggest that the inhibitory effect of MY-1250 on histamine release may be partly due to the inhibition of cyclic AMP phosphodiesterase activity.lld:pubmed
pubmed-article:7534459pubmed:languageenglld:pubmed
pubmed-article:7534459pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:citationSubsetIMlld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7534459pubmed:statusMEDLINElld:pubmed
pubmed-article:7534459pubmed:monthJanlld:pubmed
pubmed-article:7534459pubmed:issn0004-4172lld:pubmed
pubmed-article:7534459pubmed:authorpubmed-author:TakahashiKKlld:pubmed
pubmed-article:7534459pubmed:authorpubmed-author:UmezuKKlld:pubmed
pubmed-article:7534459pubmed:authorpubmed-author:AraiYYlld:pubmed
pubmed-article:7534459pubmed:authorpubmed-author:YamadaNNlld:pubmed
pubmed-article:7534459pubmed:authorpubmed-author:KadowakiSSlld:pubmed
pubmed-article:7534459pubmed:authorpubmed-author:FunayamaKKlld:pubmed
pubmed-article:7534459pubmed:issnTypePrintlld:pubmed
pubmed-article:7534459pubmed:volume45lld:pubmed
pubmed-article:7534459pubmed:ownerNLMlld:pubmed
pubmed-article:7534459pubmed:authorsCompleteYlld:pubmed
pubmed-article:7534459pubmed:pagination33-5lld:pubmed
pubmed-article:7534459pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:meshHeadingpubmed-meshheading:7534459-...lld:pubmed
pubmed-article:7534459pubmed:year1995lld:pubmed
pubmed-article:7534459pubmed:articleTitleEffect of a major metabolite of the antiallergic drug repirinast on phosphodiesterase and adenylate cyclase activities.lld:pubmed
pubmed-article:7534459pubmed:affiliationPharmaceuticals Laboratory, Mitsubishi Kasei Corporation, Yokohama, Japan.lld:pubmed
pubmed-article:7534459pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7534459pubmed:publicationTypeIn Vitrolld:pubmed